Katy Spink, COO & Managing Partner
I was born and bred in California. As an adult, I’ve been working in California’s cell & gene therapy space since long before anyone in their right mind would have used “cell & gene …
By Anthony Davies
Say what you will about Novartis; it’s always interesting over there by the Rhine. It’s been a rollercoaster of news about Zolgensma lately—from the timing of the data manipulation reporting…to the excellent 3Q earnings…to Japan and the …
By Anthony Davies
Considering the pace of the arms race for haemophilia therapies, the recently-announced collaboration between Novo and Bluebird feels quite late. Given what we know about their current progress, they’re unlikely to reach a long-term therapy first or …
Photo credit Anita Barcsa Photography
©2019 Dark Horse Consulting Group, Inc.